

Media release
30 August 2016

GLOBAL KINETICS CORPORATION ANNOUNCES NEW PRESIDENT AND CEO

MELBOURNE - Leading Australian medical technology company Global Kinetics Corporation (GKC) is delighted to announce the appointment of US-based Timothy I. Still as its new President and CEO.

Tim joins GKC at an exciting time of rapid growth for the company, driven in part by escalating demand for its clinical product, the *Parkinson's Kinetigraph™ (PKG™)*. GKC's PKG™ system is now being used to improve the management of Parkinson's disease in 200 key movement disorder clinics across the US, Europe and the Asia Pacific.

Tim's appointment followed a highly competitive global search by GKC's board to identify the right person to lead the company through its next phase of growth to profitability. Mr Still will be based in San Francisco, California – a move consistent with the company's strategy of increasing its presence in the US and other international markets.

GKC Director and Managing Director of Brandon Capital, Dr. Chris Nave said, "Tim brings a wealth of experience in healthcare and medical diagnostics to GKC. Over the past decade, Tim has successively led a number of medical technology companies, and has been responsible for building these companies into commercially viable entities. A number of them have achieved attractive exits and investor returns. He brings a unique skill-set and proven history of commercialisation which matches perfectly with GKC's rapidly expanding sales and growth strategy."

Mr. Still's background includes over 26 years of experience in healthcare and medical diagnostics. He has extensive experience in designing and implementing highly focused commercial and business development strategies within both large and small companies.

"I was initially drawn to GKC's clear vision to have a measurable impact in Parkinson's disease," Tim said. "GKC's product portfolio is first class and, combined with an impressive IP position and notable market demand, provides a compelling opportunity for near term commercial success," he said. "The market in digital health for diagnostic wearables is an exciting space, and I look forward to leading the team at GKC."

Chris Nave thanked GKC's interim leadership team, saying "GKC has been lucky to be under the outstanding stewardship of Professor Mal Horne MD, company co-founder and Chief Scientific

Officer, during the course of the search for a new CEO. Mal has led the company through a period of increasing sales and revenue diversification, while remaining steadfastly focused on what it means to make a difference for people with Parkinson's."

For media enquiries:

Michelle Goldsmith
Global Kinetics Corporation

m: +61 417 554 632

e: michelle.goldsmith@globalkineticscorp.com

Genevieve Mills

Six O'Clock Advisory

m: +61 423 939 203

e: g.mills@sixoclock.com.au

About Global Kinetics Corporation

Global Kinetics Corporation is committed to improving the lives of those with Parkinson's disease and other movement disorders with advanced medical technologies. The company was formed in 2007 to commercialise its lead product, the *Parkinson's KinetiGraph™* (PKG™). Developed by neurologists at the world-renowned Florey Institute of Neuroscience & Mental Health in Melbourne, Australia, the *Parkinson's KinetiGraph™* enables the precise monitoring, quantification and reporting of movement symptoms of neurological diseases. Global Kinetics Corporation, a privately held company, is headquartered in Melbourne, Australia with offices in Stockholm, Sweden, Minneapolis and San Francisco, USA.

For more information, visit: www.globalkineticscorporation.com